Actos (pioglitazaone) has recently been associated with the risk of bladder cancer, according to the FDA. On August 4, 2011, the FDA approved updated drug labels for the pioglitazone-containing medicines to include safety information that continued use of this medication for more than one year can be associated with an increased risk of bladder cancer.
The updated drug labels now include the following information:
... Not to use pioglitazone in patients with active baldder cancer; and
... Use pioglizaone with caution in patients with a prior history of bladder cancer.
These updated drug labels also recommend that patients should:
... 'Contact their healthcare professional if they experience any sign of blood in the urine or a red color in the urine or other symptoms such as new or worsening urinary urgency or pain on urination since starting pioglitazone, as these may be due to bladder cancer.'
Actos has also been linked to heart failure risk and other serious side affects. Despite these risks, Actos has become the number one diabetes pill after Avandia. Takeda Pharmaceuticals Co. Ltd. is the manufacturer of Actos.
Currently, Nancy Rios, 54 years old, is suing Takeda, alleging that her recurrent bladder cancer is a direct result of using Actos. She has taken Actos for more than a decade. Rios lives in Penslyvania and is worried about being able to pay for her medical bills and missing additional time from work. She said, 'I could lose my bladder and possibly need chemo.' Many others have suffered bladder cancer and serious side effects from taking Actos.
The FDA analyzed a study from the first five years of a ten year Actos safety study completed by Takedo in 2002. They concluded that the risk of bladder cancer was 40 percent higher for patients taking Actos for at least a year.
If you or a loved one has suffered a serious injury caused by a related Actos side effect, you may be able to seek compensation for your losses and suffering. Our experienced attorneys will be glad to try and advise you.
Actos-Related Bladder Cancer: June 2011 Review Of Regulatory Actions And Safety Warnings FDA And Health Canada Warn About Increased Risk, While France And Germany Suspend Actos Sales (Posted by Tom Lamb at DrugInjuryWatch.com) We will start this Actos - bladder cancer safety review with the most recent announcement, from Health Canada earlier today, June 17, 2011: Health Canada reviewing diabetes drug pioglitazone (Actos) and potential risk of bladder cancer In light of studies suggesting an increased risk of bladder cancer with the diabetes drug pioglitazone, as well as actions taken by other regulatory agencies, Health Canada is informing healthcare professionals and Canadians that it is undertaking a review of the drug's status...
FDA now says Actos - Diabetes Drug - Raises Cancer Risk The Food and Drug Administration said it is adding this information to the label for the drug after reviewing the preliminary five-year results of an ongoing 10-year study.The announcement comes after France as well as Germany stopped the sale of of Actos last week...
More signs that a diabetes drug is linked to bladder cancer Between 2004 and 2009, more than half a million adverse reactions among people taking anti-diabetic drugs were added to an official U.S. Food and Drug Administration database. Among those reports were 138 instances of bladder cancer in patients taking at least one of more than 15 different anti-diabetic drugs...